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Serotonin regulates prostate 
growth through androgen receptor 
modulation
Emanuel Carvalho-Dias1,2,3, Alice Miranda1,2, Olga Martinho1,2, Paulo Mota1,2,3, Ângela 
Costa1,2, Cristina Nogueira-Silva1,2,4, Rute S. Moura1,2, Natalia Alenina  5, Michael Bader5, 
Riccardo Autorino  1,2, Estêvão Lima1,2,3 & Jorge Correia-Pinto1,2,6
Aging and testosterone almost inexorably cause benign prostatic hyperplasia (BPH) in Human males. 
However, etiology of BPH is largely unknown. Serotonin (5-HT) is produced by neuroendocrine prostatic 
cells and presents in high concentration in normal prostatic transition zone, but its function in prostate 
physiology is unknown. Previous evidence demonstrated that neuroendocrine cells and 5-HT are 
decreased in BPH compared to normal prostate. Here, we show that 5-HT is a strong negative regulator 
of prostate growth. In vitro, 5-HT inhibits rat prostate branching through down-regulation of androgen 
receptor (AR). This 5-HT’s inhibitory mechanism is also present in human cells of normal prostate 
and BPH, namely in cell lines expressing AR when treated with testosterone. In both models, 5-HT’s 
inhibitory mechanism was replicated by specific agonists of 5-Htr1a and 5-Htr1b. Since peripheral 5-HT 
production is specifically regulated by tryptophan hydroxylase 1(Tph1), we showed that Tph1 knockout 
mice present higher prostate mass and up-regulation of AR when compared to wild-type, whereas 5-HT 
treatment restored the prostate weight and AR levels. As 5-HT is decreased in BPH, we present here 
evidence that links 5-HT depletion to BPH etiology through modulation of AR. Serotoninergic prostate 
pathway should be explored as a new therapeutic target for BPH.
Benign prostatic hyperplasia (BPH) is one of the main causes of non-neurogenic lower urinary tract symptoms 
(LUTS) in the aging male1,2. The underlying mechanism responsible for BPH is not understood, and only eluci-
dating the etiology of BPH will increase our ability to treat or even prevent its development.
Currently the most accepted hypothesis for the etiology of BPH is, that proposed by McNeal, in which BPH 
results from the reawakening of inductive potential in adult prostatic stroma in a specific prostatic region defined 
as transition zone3–5. This hypothesis claimed that the adult prostatic epithelium retains the ability to respond 
to inductive stromal signaling with new ductal branching morphogenesis6,7. However this hypothesis does not 
respond to the critical question of why this reawakening of human adult prostatic stroma occurs.
While there is no BPH without testosterone8, testosterone levels decrease with age9,10 and no direct correla-
tion between testosterone concentration and prostate volume has been established yet11. Moreover, it is widely 
accepted that physiologic concentrations of testosterone provide an excess of testosterone for optimal prostatic 
growth suggesting that testosterone is not the etiologic factor responsible for BPH12. On the other hand, several 
reports have documented an up-regulation of the androgen receptor (AR) in BPH tissue, unveiling a potential 
role for AR in BPH etiopathogenesis13–15.
The neuroendocrine prostatic cells secrete various neuroendocrine factors with 5-HT being one of the most 
abundant. The peculiar morphology of some neuroendocrine cells with dendritic processes extending to lumen 
and projections surrounding the epithelial-stroma interface justify the hypothesis that neuroendocrine products, 
namely 5-HT, could regulate prostate growth16. Notably, neuroendocrine prostatic cells are mainly located in the 
transition zone of the normal human prostate17, where BPH originates4. However, comparing BPH tissue with 
normal transition zone (without BPH) the number of neuroendocrine cells is extraordinarily decreased18–20. Also 
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5-HT was shown to be significantly depleted in BPH tissue19. Furthermore, a recent study in a large cohort of 
Scandinavian men revealed that LUTS are associated with benign prostate enlargement and to decreased plas-
matic 5-HT concentration21. These findings suggest a potential link between prostatic 5-HT depletion and BPH 
etiology; however, the function of 5-HT in regulation of benign prostate growth has never been studied.
We hypothesized that 5-HT had an inhibitory function over benign prostate growth and that suppression of 
prostatic 5-HT production could be responsible for benign prostatic growth. The aim of this study was to define 
the role of 5-HT in the regulation of benign prostatic growth and to test the pharmacologic modulation of the 
prostatic serotoninergic system as a new pharmacological target for BPH.
Results
5-HT, 5-Htr1a, and 5-Htr1b specific agonists inhibits rat ventral prostate branching through 
AR down-regulation. The new epithelial gland formation observed in BPH is normally seen only during 
prostate branching morphogenesis22. For this reason, we first tested the hypothesis that 5-HT could regulate 
prostate growth using in vitro cultures of rat ventral prostate explants (VPs) from P1 newborns. During 4 days in 
culture, 5-HT supplementation induced a significant dose-dependent inhibition of rat VPs growth (Fig. 1a), as 
expressed by decreased area (Fig. 1b), as well the number of peripheral explant buds (Fig. 1c). In medium condi-
tions without additional testosterone supplementation, inhibitory effect of 5-HT over VPs growth was maximal 
at 100 µM where a reduction of 40% in prostate area D4/D0 (p < 0.001) and a reduction of 42% in the number of 
peripheral buds D4/D0 (p < 0.001) was observed in comparison to the control group (0 µM 5-HT). As expected, 
testosterone supplementation of VPs exerted a strong stimulatory effect on prostate branching morphogenesis, 
mainly in the number of peripheral buds (Fig. 1c), but again, 5-HT at 100 µM reduced 33% the prostate area D4/
D0 (p < 0.001) and 36% the number of peripheral buds D4/D0 (p < 0.001) in comparison to control group (0 µM 
5-HT + testosterone).
From all 5-HT receptors, 5-Htr1a and 5-Htr1b were the most extensively studied in the regulation of malig-
nant prostate growth23,24, so we tested if these receptors could contribute to the 5-HT inhibitory function in nor-
mal prostate growth. By immunofluorescence, we found that both receptors are strongly expressed in rat prostate 
but with a slightly different distribution pattern with 5-Htr1a predominantly expressed in prostate epithelium 
(Fig. 1d), while 5-Htr1b being expressed both in epithelium and stroma (Fig. 1e). To determine the contribution 
of both receptors in 5-HT inhibition of prostate branching morphogenesis, VPs were treated with drugs that spe-
cifically activate 5-Htr1a or 5-Htr1b. The selective 5-Htr1a agonist 8-OH-DPAT, (Fig. 1f,g and h) and the selective 
5-Htr1b agonist, anpirtoline, (Fig. 1i, j and k) induced a significant dose-dependent inhibition of VPs growth. The 
inhibitory effect was maximal in VPs supplemented with testosterone and treated with 100 µM of anpirtoline, 
where a reduction of 39% in prostate area D4/D0 (p < 0.001) and a reduction of 66% in the number of peripheral 
buds D4/D0 (p < 0.001) was observed in comparison to the control group (0 µM anpirtoline + testosterone).
Since, androgens are a major prostatic stimulatory factor, we asked if the 5-HT inhibitory effect was related 
to the AR stimulatory pathway. By western blot analysis we showed that testosterone supplementation induced 
Figure 1. 5-HT, 5-Htr1a specific agonist and 5-Htr1b specific agonist inhibit prostate branching morphogenesis. 
(a) Photographs of representative VPs at D0 and at D4 of culture treated with different 5-HT concentrations. 
(b) Morphometric analysis of the effect of 5-HT on VPs area and (c) number of peripheral buds (n ≥ 12 VPs 
per group). (d) Immunofluorescence analysis of 5-Htr1a and (e) 5-Htr1b expression in the rat prostate. (f) 
Photographs of representative VPs at D0 and at D4 of culture treated with different 8-OH-DPAT concentrations. 
(g) Morphometric analysis of the effect of 8-OH-DPAT on VPs area and (h) number of peripheral buds 
(n ≥ 12 VPs per group). (i) Photographs of representative VPs at D0 and at D4 of culture treated with different 
anpirtoline concentrations. (j) Morphometric analysis of the effect of Anpirtoline on VPs area and (k) number 
of peripheral buds (n ≥ 12 VPs per group). Error bars indicate s.e.m. ***p < 0.001; two-way ANOVA and 
Bonferroni post hoc test. VPs, ventral prostate explants; D0, day 0; D4, day 4; 5-HT, serotonin.
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AR up-regulation, but 5-HT treatment significantly decreased AR expression either with or without testosterone 
supplementation (Fig. 2a and b) suggesting that the inhibitory function of 5-HT could be related to inhibition 
of the AR pathway. Similarly, both the selective 5-Htr1a agonist 8-OH-DPAT, (Fig. 2a and c) and the selective 
5-Htr1b agonist, anpirtoline, (Fig. 2a and d) induced a significant AR down-regulation, more evident in anpir-
toline treated VPs. Taken together these results indicate that in vitro 5-HT inhibits rat prostate growth through 
5-Htr1a and 5-Htr1b, by down-regulating AR.
5-HT, 5-Htr1a or 5-Htr1b specific agonists inhibit growth of androgen sensitive human benign 
prostate cells through AR down-regulation. Next, we asked if this mechanism is also present in human 
prostate. With this purpose we performed in vitro 5-HT treatment of different human cell lines from epithe-
lium of BPH (BPH-1), normal prostate epithelium (PNT1A) and normal prostate stroma (WPMY-1). We found 
that 5-HT significantly reduced cell viability of BPH-1 and WPMY-1 namely in the presence of testosterone but 
without changing PNT1A cell viability (Fig. 3a,b,c and Supplementary Fig. 1). The inhibitory effect of 5-HT was 
maximal in BPH-1 cells supplemented with testosterone. Under these conditions, 100 µM of 5-HT decreased cell 
viability by 35% compared to control (0 µM 5-HT + testosterone) (p < 0.001).
Next, we tested if the growth inhibitory function of 5-HT in androgen human prostate cells BPH-1 and 
WPMY-1 was mediated by 5-Htr1a and 5-Htr1b. First, we showed that both receptors are expressed in the three 
human prostate cell lines (Fig. 3d) and that their specific agonists significantly inhibited cell viability (Fig. 3e–j 
and Supplementary Fig. 1) almost exclusively in the presence of testosterone, but again only in BPH-1 and 
WPMY-1, without any inhibitory effect in PNT1A cells.
Figure 2. 5-HT, 5-Htr1a specific agonist and 5-Htr1b specific agonist down-regulates AR expression in rat 
ventral prostate. (a) Western blot analysis of AR expression in prostate explants treated with increasing doses 
of 5-HT, specific 5-Htr1a agonist, 8-OH-DPAT, and specific 5-Htr1b agonist, anpirtoline. (b) Quantification 
of AR protein in VPs treated with different concentrations of 5-HT in medium conditions without or with 
testosterone supplementation, n ≥ 3 (each sample contained a pool of 4 VPs). (c) Quantification of AR 
protein in VPs treated with different concentrations of 8-OH-DPAT in medium conditions without or with 
testosterone supplementation, n ≥ 3 (each sample contained a pool of 4 VPs). (d) Quantification of AR protein 
in VPs treated with different concentrations of Anpirtoline in medium conditions without or with testosterone 
supplementation, n ≥ 3 (each sample contained a pool of 4 VPs). Error bars indicate s.e.m. n.s. non-significant; 
*p < 0.05; **p < 0.01; ***p < 0.001; two-way ANOVA and Bonferroni post hoc test. VPs, ventral prostate 
explants; AR, androgen receptor; AU, arbitrary units; 5-HT, serotonin.
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Additionally, Ki-67 staining confirmed that proliferation of BPH-1 and WPMY-1 cells supplemented with 
testosterone was significantly reduced by 5-HT treatment (Fig. 4a and c), while PNT1A cells proliferation was 
not affected (Fig. 4b). Similarly, both specific agonists of 5-Htr1a and 5-Htr1b strongly inhibited cell proliferation 
(Fig. 4d–i) but again only in BPH-1 and WPMY-1 cells.
Next, we investigated if this inhibitory function of 5-HT, 5-Htr1a and 5-Htr1b specific agonists was related to 
changes in the AR pathway. We observed that testosterone induced an up-regulation of AR in both BPH-1 and 
WPMY-1 cells. 5-HT, 5-Htr1a and 5-Htr1b specific agonists inhibited the AR up-regulation induced by testos-
terone in both BPH-1 and WPMY-1 cells (Fig. 5b). Regarding 5-HT effect in AR down-regulation this was very 
significant in WPMY-1 cells after testosterone supplementation (p < 0,001) while in BPH-1 cells a non-significant 
down-regulation of AR was observed (Fig. 5c and d). Also for both 5-Htr1a and 5-Htr1b specific agonists only 
Anpirtoline induced a significant down-regulation of AR in both BPH-1 and WPMY-1 cells (Fig. 5d,e,g,h). 
Additionally, by immunofluorescence analysis we observed that expression of AR after testosterone treatment 
was decreased in BPH-1 cells treated with 5-HT, 5-Htr1a and 5-Htr1b specific agonists (Supplementary Fig. 2).
Remarkably, the absence of inhibitory action of 5-HT, 5-Htr1a and 5-Htr1b specific agonists on PNT1A cells 
viability and proliferation, even in presence of testosterone, co-existed with a complete absence of AR expression 
in these cells (Fig. 5a). These data strongly argue that 5-HT’s inhibitory function on growth of benign human 
prostate cells is related with the suppression of the AR pathway.
In vivo ablation of peripheral 5-HT synthesis in mice induces benign prostatic growth. 5-HT 
synthesis is initiated by tryptophan hydroxylase (Tph). Tph type 1 (Tph1) and 2 (Tph2) regulate 5-HT production 
in non-neuronal and neuronal tissues, respectively25,26. The majority of 5-HT in the body is produced by Tph1. 
In fact, Tph1−/− mice exhibit very low levels of circulating 5-HT, while brain serotonin is not affected25. Based 
on our in vitro findings which suggest that 5-HT has a strong inhibitory action on prostate growth through 
down-regulation of AR, we used Tph1−/− mice to evaluate the effect of peripheral 5-HT depletion on mouse pros-
tate gland growth. Remarkably, Tph1−/− mice exhibited a significantly 37% higher prostate-to-body weight ratio 
compared to wild-type at 20 weeks (p < 0.001) (Fig. 6a and b) without changes in body weight (Supplementary 
Fig. 3a). Interestingly, histology of the prostate gland revealed that Tph1−/− mice exhibit areas of hyperplasia 
in epithelium and stroma (Fig. 6a, lower panel). To determine if 5-HT treatment could revert higher prostate 
mass in Tph1−/− mice, we performed intraperitoneal injections of 5-HT at 10 consecutive days. 5-HT treatment 
resulted in significant mass reduction in prostate gland compared to levels similar to the wild-type (Fig. 6c and d) 
again without affecting animal weight (Supplementary Fig. 3b). Next, we asked if the higher prostate mass in 
Tph1−/− mice was associated with different expression of AR. We could not demonstrate significant differences 
Figure 3. 5-HT, 5-Htr1a specific agonist and 5-Htr1b specific agonist inhibits cell viability in BPH-1 and 
WPMY-1 human prostatic cells without any effect in PNT1A cells. (a,b,c) Effect of 5-HT on cell viability 
analyzed by MTS assay in BPH-1, PNT1A and WPMY-1 cells. (d) Immunofluorescence analysis of 5-Htr1a and 
5-Htr1b expression in BPH-1, PNT1A and WPMY-1 cells. (e,f,g) Effect of 5-Htr1a specific agonist, 8-OH-DPAT, 
and (h,i,j) 5-Htr1b specific agonist, Anpirtoline, on cell viability analyzed by MTS assay in BPH-1, PNT1A 
and WPMY-1 cells. The data are expressed relative to control condition (0 µM 5-HT without testosterone 
supplementation) and were reproduced in at least three independent experiments. Error bars indicate s.e.m. n.s. 
non-significant; 5-HT, serotonin; *p < 0.05; **p < 0.01; ***p < 0.001; two-way ANOVA and Bonferroni post 
hoc test.
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of AR expression by western blot analysis in total prostate (data not shown), however by immunofluorescence 
dorsolateral prostate of Tph1−/− mice appeared to express more AR (Fig. 6e, lower panel). So, we investigated 
and demonstrated by qRT-PCR that the dorsolateral prostate of Tph1−/− mice has increased levels of AR mRNA 
expression, while 5-HT treatment partially restores it to levels to wild-type mice (Fig. 6e, upper panel), reinforc-
ing our hypothesis.
It is well established that castration induces a strong reduction in size of the prostate gland as well as in seminal 
vesicles, while testosterone supplementation makes both organs return to normal size27,28. Interestingly, also sem-
inal vesicles of Tph1−/− mice were significantly larger than the ones of wild-type (Fig. 6f) suggesting that 5-HT 
could regulate androgen sensitivity not only in prostate gland but also in seminal vesicles. Again, we observed that 
the mass of seminal vesicles was partially restored by 5-HT treatment in Tph1−/− mice (Fig. 6g).
Figure 4. 5-HT, 5-Htr1a specific agonist and 5-Htr1b specific agonist inhibits cell proliferation in BPH-1 and 
WPMY-1 human prostatic cells without any effect in PNT1A cells. (a,b,c) Effect of 5-HT, (d,e,f) 5-Htr1a specific 
agonist, 8-OH-DPAT, and (g,h,i) 5-Htr1b specific agonist, Anpirtoline, on cell proliferation of BPH-1, PNT1A 
and WPMY-1 cells as quantified by Ki-67 positive cells/total cell number ratio. The data are expressed relative 
to control condition (0 µM 5-HT without testosterone supplementation) and were reproduced in at least three 
independent experiments. Error bars indicate s.e.m. n.s. non-significant; 5-HT, serotonin; *p < 0.05; **p < 0.01; 
***p < 0.001; two-way ANOVA and Bonferroni post hoc test.
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Lastly, we tested if wild-type mice challenged with 5-HT treatment continue responding to 5-HT’s inhibitory 
action, and we demonstrated that both prostate gland (Fig. 6h) as well as seminal vesicle mass (Fig. 6i) were 
reduced while animal weight was not affected (Supplementary Fig. 3c).
Discussion
Currently, the etiology of BPH is unknown. However, it is accepted today that BPH is a consequence of aging and 
the simultaneous presence of testosterone3. BPH almost universally affects human males and a significant part 
of men will develop bothersome LUTS because of benign prostate enlargement. Although some of these men 
respond to current medical treatment (mainly α1-adrenoreceptors antagonists and 5 α-reductase inhibitors) a 
large portion continues to need a surgical procedure to treat resistant LUTS or have even more serious complica-
tions of BPH29, creating the emerging necessity for novel therapies.
In this study, we investigated the function of 5-HT in the regulation of non-malignant prostatic growth. Here, 
we demonstrated for the first time in several in vitro and in vivo models that 5-HT is a powerful negative regulator 
of prostatic growth through down-regulation of AR. We found that 5-Htr1a and 5-Htr1b are strongly expressed 
in the rodent prostate gland as well in human benign prostate cells, and that both receptors could mediate the 
inhibitory action of 5-HT on prostate growth.
Our in vitro and animal findings lead us to propose a new mechanism to explain the development of BPH in 
humans (Fig. 7). Our proposed model explains how the depletion of neuroendocrine cells and serotonin observed 
in prostatic transition zone with aging18–20, could be the etiologic factor responsible for the initiation and pro-
gression of BPH. In our model, the depletion of serotonin induces an up-regulation of androgen receptor in the 
prostatic transition zone leading to the stimulation of benign prostatic growth in this specific prostatic region.
Our neuroendocrine model for the etiopathogenesis of BPH would resolve an intriguing question about the 
crucial participation of androgens in the development of BPH. Previous studies have showed that testosterone 
does not increase with aging and some studies have even reported that plasmatic testosterone is decreased in the 
aging human male9–11. In a similar way, intraprostatic testosterone, in particular DHT, are not increased in BPH 
comparatively to normal prostate30 and even the administration of testosterone in supra-physiologic concentra-
tions to eugonadal men does not induce the development of BPH31,32. This data were the basis for the saturation 
model of prostate growth proposed by Morgentaler et al. suggesting that prostate gland growth is extraordinarily 
sensitive to low androgen concentrations (near the castrate range) but insensitive to androgen concentrations 
above a certain saturation point12. The critical point, in saturation model is that the rate-limiting step for prostatic 
growth, which is the concentration of AR. Recent studies demonstrated that AR is in fact up-regulated in stroma 
Figure 5. 5-HT, 5-Htr1a specific agonist and 5-Htr1b specific agonist down-regulates AR expression in human 
prostatic cells. (a) Western blot analysis of AR expression in the three cell lines after 5-HT, 8-OH-DPAT and 
anpirtoline treatment. (b) Quantification of AR in BPH-1 and (c) WPMY-1 cells after 5-HT treatment in 
medium conditions without or with Testosterone supplementation. (d) Quantification of AR protein levels in 
BPH-1 and (e) WPMY-1 cells after 8-OH-DPAT treatment in medium conditions without or with Testosterone 
supplementation. (f) Quantification of AR protein levels in BPH-1 and (g) WPMY-1 cells after Anpirtoline 
treatment in medium conditions without or with Testosterone supplementation. The data are expressed relative 
to control condition (0 µM 5-HT without testosterone supplementation) and were reproduced in at least three 
independent experiments. Full, uncropped gel images are shown. Error bars indicate s.e.m. n.s. non-significant; 
*P < 0.05; **P < 0.01; ***P < 0.001; two-way ANOVA and Bonferroni post hoc test. AR, androgen receptor; 
5-HT, serotonin.
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and epithelium of BPH tissue comparatively to normal prostate, implicating AR in etiophatogenesis of BPH13–15. 
Our findings seem to provide an explanation for this current view about the participation of androgens in the 
development of BPH. In this way, the loss of neuroendocrine cells and serotonin in prostatic transition zone 
up-regulates the AR and then permits the development of BPH, even with a decreased plasmatic concentration 
of androgens observed in the aging male.
Our first in vitro experimental approach focused on the function of 5-HT in the regulation of rat prostate 
branching morphogenesis. Because BPH is the result of new branching morphogenesis, this model permits the 
study the influence of 5-HT exactly in the mechanism by which BPH develops and progresses. Here, we demon-
strate that 5-HT strongly inhibit the branching morphogenesis of the prostate gland through down-regulation of 
AR. In fact, other organs like the prostate which have a development process of branching morphogenesis, such 
as the mammary gland, 5-HT also have demonstrated a development inhibitory action33.
Although new in the prostate gland, the serotoninergic inhibitory mechanism through down-regulation of 
AR, is well known in the brain. In fact, the complete masculinization of the brain is dependent of a perinatal surge 
of testosterone and a simultaneous decrease in hypothalamic 5-HT concentrations34. In the brain, it has been 
demonstrated that regulation of 5-HT concentration is crucial for normal sexual differentiation, where 5-HT 
down-regulates AR35,36. In agreement with our findings, Sayed et al. demonstrated that dapoxetine decreased AR 
expression and prevents testosterone-induced BPH in rats37. However, both in brain and prostate the full mecha-
nism responsible for this down-regulation remains to be elucidated.
The most described 5-HT receptors in prostatic cells, are the 5-Htr1a and 5-Htr1b. Therefore, we character-
ize its expression in rat prostate for the first time. As we demonstrated both 5-Htr1a and 5-Htr1b are strongly 
expressed in rat prostate and the activation of these receptors resulted in a significant inhibition of prostate 
branching morphogenesis, which also occurred through down-regulation of AR. In human prostatic cells the 
function of 5-HT, 5-Htr1a, and 5-Htr1b have been previously studied but only in malignant cells23,24. These pre-
vious reports showed that 5-HT has a proliferative effect in several malignant cell lines through 5-Htr1a and 
5-Htr1b. Curiously, this stimulatory effect was mainly evident in androgen-insensitive cells23. Here we studied, for 
Figure 6. Genetic deletion of Tph1 increases prostate gland mass. (a) Representative photographs of prostates 
from 20 week-old wild-type and Tph1−/− mice (Top). Images from H&E staining of wild-type and Tph1−/− 
prostates (n = 5 per genotype) (Bottom). (b) Prostate-to-body weight ratio of Tph1−/− mice compared to 
wild-type at different ages (n = 6–7 for wild-type and Tph1−/− mice, for each time point). (c) Representative 
photographs of prostates and (d) prostate-to-body weight ratio from 20 week-old wild-type, Tph1−/− treated 
with saline and Tph1−/− treated with 5-HT (n = 7 WT; n = 6 Tph1−/− +Saline; n = 7 Tph1−/− + 5-HT). (e) qRT-
PCR for AR expression in dorsolateral lobe of 20 week-old wild-type, Tph1−/− treated with saline and Tph1−/− 
treated with 5-HT (n = 4 wild-type; n = 4 Tph1−/− +Saline; n = 3 Tph1−/− + 5-HT) (Top). Immunofluorescence 
analysis of AR expression in dorsolateral prostate of WT and Tph1−/− mice (200x) (Bottom). (f) Seminal 
vesicle-to-body weight ratio of Tph1−/− mice compared to wild-type mice at different ages (n = 6–7 for wild-
type and Tph1−/−; mice, for each time point). (g) Seminal vesicle-to-body weight ratio from 20 week-old wild-
type, Tph1−/− treated with saline and Tph1−/− treated with 5-HT (n = 7 WT; n = 6 Tph1−/− + Saline; n = 7 
Tph1−/− + 5-HT). (h) prostate-to-body weight ratio and (i) seminal vesical-to-body weight ratio in wild-type 
mice treated with Saline compared to wild-type mice treated with 5-HT during 10 consecutive days (n = 10 for 
each group). n.s. non-significant; AR, androgen receptor; 5-HT, serotonin; *p < 0.05; **p < 0.01; ***p < 0.001; 
(B,F) two-way and (D,G) one-way ANOVA and Bonferroni post hoc test. (H,I) Student t test.
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the first time, the function of 5-HT, 5-Htr1a, and 5-Htr1b in human benign prostatic cells. We demonstrated that 
5-HT inhibits proliferation of androgen sensitive benign prostatic cells, and this inhibitory function was associ-
ated to a down-regulation of AR. This different growth function of 5-HT in benign and malignant cells remains 
unexplained but the predominant stimulatory effect of 5-HT in androgen-insensitive malignant cells suggests that 
castration resistance could change the phenotypic response of prostatic cell to neuroendocrine products.
Finally, to test in vivo our mechanistic approach to the etiopathogenesis of BPH, we genetically ablated the 
peripheral production of 5-HT. Using Tph1−/− mice we demonstrated that prostatic 5-HT depletion induces 
benign prostatic growth. The inhibition of peripheral 5-HT synthesis in mice, through genetic deletion of Tph1, 
simulates a decrease in the prostate transition zone 5-HT observed in the aging male. This led us to propose that 
the decrease in neuroendocrine cells and 5-HT in the human transition zone could contribute to the develop-
ment of BPH. The increased mass of Tph1−/− prostates was associated to an up-regulation of AR in dorso-lateral 
prostate samples suggesting that, at least in part, the excessive prostatic growth in Tph1−/− could be attributed to 
AR up-regulation.
In conclusion, our findings suggest that 5-HT is a strong negative regulator of prostate growth through AR 
down-regulation. As 5-HT is decreased in BPH, we present here evidence that links 5-HT-producing neuroendo-
crine cell depletion to BPH etiology. Therefore, this new described serotoninergic inhibitory pathway over benign 
prostatic growth should be explored as a new target for BPH treatment.
Methods
Ethics and animal work. Mice and rats were maintained in accordance with the guidelines of “Guide to the 
Care and Use of Experimental Animals” National Academy of Science, and the EU Directive 2010/63/EU. This 
study was approved by the Animal Ethics Committee of the Institution were the study was performed (SECVS 
003/2016) and by the National Competent Authority for Animal Protection (DGAV 0421/000/000/2016).
Drugs. 5-HT and testosterone were purchased from Sigma-Aldrich (St Louis, Missouri). The 5-Htr1a spe-
cific agonist, 8-OH-DPAT and the 5-Htr1b specific agonist, Anpirtoline, were purchased from Tocris-Bioscience 
(Bristol, UK).
Rat ventral prostate cultures. Newborn male Sprague-Dawley rats were sacrificed 24-hours after birth. 
Ventral prostate lobes were microdissected using a stereomicroscope (Leica MZ6, Switzerland) and processed for 
organ culture. Organ culture was performed as previously described38. Briefly, rat ventral prostates (VPs) from 
P1 newborns were cultured for 4 days at 37 °C in a humidified atmosphere of 5% CO2. Medium and VPs were 
transferred to porous membranes (Millicell CM filters, Millipore Corp., Bedford, Massachusetts) in 12 well plate 
Figure 7. Neuroendocrine hypothesis for etiopathogenesis of benign prostatic hyperplasia. (a) In young human 
male, prostate transition zone is enriched with 5-HT producing neuroendocrine cells. Serotonin is secreted 
to the epithelium-stroma interface and through activation of 5-Htr1a and 5-Htr1b, both in epithelium and 
stroma, the expression of AR is decreased. Yet, more testosterone is delivery to prostate, down-regulated AR 
limits benign prostate growth. (b) In aged human male, transition zone loses 5-HT producing neuroendocrine 
cells causing a depletion in local 5-HT. As a consequence 5-Htr1a and 5-Htr1b release their inhibition over AR 
expression. Although with aging the delivery of testosterone to the prostate is decreased the up-regulation of 
AR induces the development of BPH. 5-HT, serotonin; AR, androgen receptor; DHT, Dihydrotestosterone; NE, 
neuroendocrine; T, testosterone.
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for floating explant cultures. Each VPs were dipped into 500 μl of 1:1 mixture of DMEM and Ham’s F-12 nutrient 
supplemented with 100 μg/mL streptomycin, 100 units/mL penicillin, 10 µg/mL transferrin and 10 µg/mL insulin. 
Media were replenished at 48 hours of culture. Branching morphogenesis in all groups was monitored daily by a 
stereomicroscope and photographs were taken at day 0 and day 4. The number of peripheral buds was manually 
counted and the prostate tissue area was measured in ImageJ using the beProstate plugin (Version 1.0) (developed 
by Biomedical Engineering Solutions Research Group, Life and Health Sciences Research Institute, University of 
Minho; available at http://www.besurg.com/sites/default/files/beProstateApp.zip). The differences between day 
0 (D0: 0 hours) and day 4 (D4: 96 hours) of culture, were expressed as D4/D0 ratio. A total of 427 VPs were cul-
tured divided in three experimental groups: 5-HT, 8-OH-DPAT and anpirtoline. For each experimental group 
a dose-effect approach was used. Furthermore, each experimental group was cultured either with or without 
testosterone supplementation of media ([testosterone] = 10−8 M).
Human prostate cell lines cultures. Three human cell lines were used: PNT1A and WPMY-1 were 
obtained from American Type Culture Collection (ATCC, Manassas, Virginia) and BPH-1 which was obtained 
from DSMZ (German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany). All the cell 
lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM 1x, high glucose; Gibco, Invitrogen, Grand 
Island, New York) supplemented with 10% FBS (Gibco, Invitrogen, Grand Island, New York) and 1% penicillin/
streptomycin solution (DMEM-10), at 37 °C and 5% CO2. For the viability assay, the cells were plated into 96-well 
plates at a density of 3 × 103 cells per well and allowed to adhere overnight in DMEM medium containing 10% 
FBS. Subsequently, the cells were treated with increasing concentrations of 5-HT, 8-OH-DPAT and Anpirtoline 
diluted in 0.5% FBS culture medium, with or without testosterone (10−8M) supplementation. After 72 hours of 
incubation, cell viability was quantified using CellTiter 96 Aqueous Cell Proliferation Assay (MTS) (Promega, 
Madison, Wisconsin). The mean percentage of viable cells relative to the vehicle alone (considered as 100% via-
bility) was determined, and the final results were expressed in relation to the control (adjusted to 1). For the 
proliferation assay, we evaluated the number of Ki-67 positive cells by immunofluorescence. The cells were plated 
in glass coverslips placed into 12-well plates at a density of 5 × 104 cells per well, and allowed to adhere over-
night. Subsequently, the cells were treated with 5-HT (100 µM), 8-OH-DPAT (100 µM) and Anpirtoline (100 µM) 
diluted in 0.5% FBS culture medium, with or without testosterone (10−8M) supplementation. The total number 
of cells and the Ki-67 positive cells were manual counted using a fluorescence microscopy (BX16; Olympus). 
The ratio of Ki-67 positive cells per total number of cells was determined, and the final results were expressed in 
relation to the control (adjusted to 1).
Tph1−/− Mice and in vivo studies. Only male mice were used for in vivo experiments. They were housed 
in specific pathogen-free conditions in a room maintained at a constant temperature of 23 °C on a 12-h light-dark 
cycle. Food and water were provided ad libitum. All treatment groups were age matched and randomized to 
treatment at the initiation of an experiment. The researchers performing the experiments were blinded to experi-
mental groups during all testing. Animals were excluded from analysis if signs of fight with skin lesions were pres-
ent. Tph1−/− mice on a C57BL/6 background were provided by M. Bader (Max Delbrück Center for Molecular 
Medicine, Berlin, Germany). For assessment of the morphological evolution with age both male wild-type and 
Tph1−/− mice were sacrificed at different time points (at least 6 animals for both groups at each time-point): 7, 12, 
16 and 20 weeks-old. For pharmacological studies, wild-type and Tph1−/− mice with 19 week-old were treated 
daily with intraperitoneal injections of 0.9% saline or 5-HT (100 mg/Kg) during 10 consecutive days (at least 6 
animals for each group). Mice were sacrificed and prostate tissue (all lobes combined) and seminal vesicles were 
micro dissected away from other urogenital and fat tissues. Total prostate was weighted immediately after dissec-
tion. The right lobes were separated from the left and processed for histology or western blotting. For histologic 
analysis hemi-right prostate was fixed in 10% PFA, processed and embedded in paraffin and stained with hema-
toxylin and eosin (H&E). Hemi-left prostate was separated in three lobes (ventral, dorsolateral and anterior) and 
processed to qRT-PCR.
Immunofluorescence analysis. Immunofluorescence for AR, Ki-67, 5-Htr1a and 5-Htr1b was performed 
on formalin-fixed and paraffin-embedded rat ventral prostates or in human prostate cell lines. Briefly, depa-
raffinized and rehydrated slides were submitted to adequate heat-induced antigen retrieval for 20 min at 98 °C 
with 10 mM citrate buffer (pH 6.0). Regarding cell lines, all of them were plated in glass coverslips placed into 
12-well plates at a density of 5 × 105 cells per well, and allowed to adhere overnight. Then, the cells were fixed in 
cold methanol by 5 minutes at −20 °C. In both paraffin and cell, for block unspecific ligations the cells/tissues 
were incubated with a solution of PBS containing 10% FBS for 30 minutes at room temperature followed by 
incubation with a primary antibody against AR (1:1000 dilution; sc-816: Santa Cruz Biotechnology, Santa Cruz, 
California), Ki-67 (1:100 dilution, AP10244C; Gennova, Sevilla, Spain), 5-Htr1a (1:100 dilution; sc-10801: Santa 
Cruz Biotechnology, Santa Cruz, California) and 5-Htr1b (1:100 dilution; sc-28937: Santa Cruz Biotechnology, 
Santa Cruz, California). The cells/tissues were then washed in a PBS solution with 0.5% FBS and incubated 
with a goat anti-rabbit antibody conjugated with FITC for cells and with TRITC for tissues (dilution 1:500, Life 
Technology, Carlsbad, California) for 1 hour at room temperature in the dark. Finally, the cells were counter-
stained with 40,6-diamidino-2-phenylindole (DAPI). The images were obtained using a fluorescence microscopy 
(BX16; Olympus).
Western blot analysis. Western blot analysis for androgen receptor (AR) was done in both VPs, mouse 
prostate tissue and in human cell lines. All the samples were properly processed for western blot analysis and 
lysed in a buffer containing 50 mM Tris pH 7.6–8, 150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 10 mM NaF, 
10 mM NaPyrophosphate, 1% NP-40 and 1/7 of Protease cocktail inhibitors (Roche). Western blotting was done 
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using standard 10% SDS-PAGE gels, loading 20 µg of protein per lane. For AR detection a specific antibody was 
used (1:1000 dilution; sc-816: Santa Cruz Biotechnology, Santa Cruz, California). β-Actin was used for loading 
control (1:500 dilution; sc-1616; Santa Cruz Biotechnology, Santa Cruz, California). After incubation with appro-
priate secondary antibodies, they were detected by chemiluminescence (Thermo Scientific Pierce ECL Western 
Blotting) in ChemiDoc™ XRS + System (Bio-Rad). Quantification of western blot results was done using the 
band densitometry analysis, performed with ImageJ software.
RNA extraction and qRT-PCR. Total RNA was isolated from the dorsolateral prostate of different 
groups with Trizol (Invitrogen, Carlsbad, California). Then, after quantification using the NanoDrop®, 500 ng 
of total RNA was reverse transcribed into first strand cDNA using the iScript™ cDNA Synthesis Kit (Bio-Rad 
Laboratories, Hercules, California). Primers used to measure the expression levels of AR was designed using the 
Primer3 software, on the basis of the respective GenBank sequence. All accession numbers and primer sequences 
are available on request. The reference gene for hypoxanthine guanine phosphoribosyl transferase (Hprt) (acces-
sion number from GenBank: NM_013556) was used as an internal standard for the normalization of the expres-
sion of selected transcripts. qRT-PCR was performed on a CFX 96TM real time system instrument (Bio-Rad 
Laboratories, Hercules, California), with the QuantiTect SYBR Green RT-PCR reagent kit (Qiagen, Hamburg, 
Germany), using equal amounts of RNA from each one of the samples. Product fluorescence was detected at the 
end of the elongation cycle. All melting curves exhibited a single sharp peak at the expected temperature.
Statistics. Data are presented as mean ± SEM. Statistical analysis was performed using GraphPad Prism by 
Student’s t test or ANOVA where appropriate. A Bonferroni post hoc test was used to test for significant differences 
revealed by ANOVA. Statistical significance was confirmed at p < 0.05.
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